These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19955336)

  • 1. Potential role of everolimus in inducing cholestasis.
    Pantano F; Santini D; Guida F; Vincenzi B; Tonini G
    Ann Oncol; 2010 Feb; 21(2):433. PubMed ID: 19955336
    [No Abstract]   [Full Text] [Related]  

  • 2. Temsirolimus (Torisel) for advanced renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
    [No Abstract]   [Full Text] [Related]  

  • 3. Everolimus for the treatment of advanced renal cell carcinoma.
    Amato R
    Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumocystis jirovecii pneumonia in everolimus-treated renal cell carcinoma.
    Loron MC; Grange S; Guerrot D; Di Fiore F; Freguin C; Hanoy M; Le Roy F; Poussard G; Etienne I; Legallicier B; Pfister C; Godin M; Bertrand D
    J Clin Oncol; 2015 Mar; 33(8):e45-7. PubMed ID: 24638002
    [No Abstract]   [Full Text] [Related]  

  • 5. Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies.
    Patel SB; Stenehjem DD; Gill DM; Tantravahi SK; Agarwal AM; Hsu J; Vuong W; Pal SK; Agarwal N
    Clin Genitourin Cancer; 2016 Apr; 14(2):153-9. PubMed ID: 26781820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dystrophic calcification after palliative chemotherapy in a patient with renal cell carcinoma.
    Lim DH; Lee SI; Park KW
    Korean J Intern Med; 2017 Mar; 32(2):380-381. PubMed ID: 28049213
    [No Abstract]   [Full Text] [Related]  

  • 7. Everolimus in renal cell carcinoma.
    Wang Y
    Drugs Today (Barc); 2010 Aug; 46(8):557-66. PubMed ID: 20830316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus in metastatic renal cell carcinoma: preliminary experience from Chang Gung Memorial Hospital.
    Huang WK; Liaw CC; Pang ST; Chuang CK; Chiang YJ; Wu CT; Chang YH; Wang HM; Lin YC; Hsieh JJ; Ou LY; Tsai SI; Yang CH; Yang CT; Chang JW
    Chang Gung Med J; 2012; 35(5):402-7. PubMed ID: 23127345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus and pazopanib: two new drugs for renal cell cancer.
    Med Lett Drugs Ther; 2010 May; 52(1337):33-4. PubMed ID: 20431519
    [No Abstract]   [Full Text] [Related]  

  • 10. [Medical treatment of renal cell carcinoma].
    Guy L; Bay JO; Bastide C; Mahammedi H; Bruyere F; Karsenty G
    Prog Urol; 2013 Nov; 23(15):1225-37. PubMed ID: 24183081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib re-challenge in metastatic renal cell carcinoma treated sequentially with tyrosine kinase inhibitors and everolimus.
    Paule B; Brion N
    Anticancer Res; 2011 Oct; 31(10):3507-10. PubMed ID: 21965770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Experience with everolimus therapy for patients with metastatic renal cancer in Hungary].
    Maráz A; Bodoky G; Dank M; Géczi L; Kahán Z; Mangel L; Révész J; Szűcs M
    Magy Onkol; 2014 Mar; 58(1):4-9. PubMed ID: 24712001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
    Grgic T; Mis L; Hammond JM
    Ann Pharmacother; 2011 Jan; 45(1):78-83. PubMed ID: 21177421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
    Grünwald V; Karakiewicz PI; Bavbek SE; Miller K; Machiels JP; Lee SH; Larkin J; Bono P; Rha SY; Castellano D; Blank CU; Knox JJ; Hawkins R; Anak O; Rosamilia M; Booth J; Pirotta N; Bodrogi I;
    Eur J Cancer; 2012 Feb; 48(3):324-32. PubMed ID: 21803569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY; Grossman AB; Bukowski RM
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammalian target of rapamycin (mTOR)-related non-infectious pneumonitis: a potential biomarker of clinical benefit?
    Rodriguez-Vida A; Chau NM; Chowdhury S
    BJU Int; 2014 Mar; 113(3):350-1. PubMed ID: 24528875
    [No Abstract]   [Full Text] [Related]  

  • 17. [Management of side effects of everolimus treatment for metastatic renal cell carcinoma].
    Mikami K; Hongo F; Miki T
    Hinyokika Kiyo; 2012 Nov; 58(11):647-50. PubMed ID: 23254794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of everolimus in renal cell cancer.
    Amato R; Stepankiw M
    Expert Opin Pharmacother; 2013 Jun; 14(9):1229-40. PubMed ID: 23578333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory effects of everolimus in a long responsive patient with metastatic renal cell carcinoma.
    Thiery-Vuillemin A; Laheurte C; Mansi L; Royer B; Pivot X; Borg C; Adotevi O
    J Immunother; 2014 Jan; 37(1):51-4. PubMed ID: 24316556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
    Calvo E; Escudier B; Motzer RJ; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Ravaud A; Kim D; Panneerselvam A; Anak O; Figlin RA
    Eur J Cancer; 2012 Feb; 48(3):333-9. PubMed ID: 22209391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.